Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
European Cancer Organisation: Time To Act
Professor Mark Lawler - Queens University Belfast, Belfast, UK
European Cancer Organisation: Time To Act ( Professor Mark Lawler - Queens University Belfast, Belfast, UK )
19 May 2021
Rare inherited pathogenic germline variants observed in sporadic paediatric neur...
Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )
11 May 2021
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA comp...
Dr Matthew Marx - Mirati Therapeutics, San Diego, USA
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )
30 Apr 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutan...
Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )
13 Apr 2021
Clinical validation of a targeted methylation-based multi-cancer early detection...
Dr Eric Klein - Cleveland Clinic, Cleveland, USA
Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )
1 Apr 2021
Highlights from AORTIC Cancer Genomics Conference 2021
Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, ...
Highlights from AORTIC Cancer Genomics Conference 2021 ( Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, Accra, Ghana )
30 Mar 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )
29 Mar 2021